SCHEMBL1853218

SCHEMBL1853218

CN(C)C(=O)c1ccc(N)c(C(=O)N(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAP4K1 Q92918 8/20 0.45
HSP90AA1 P07900 1/20 0.44
PDK2 Q15119 1/20 0.44
ABL1 P00519 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 4/20 0.42
MAPK1 P28482 2/20 0.42
GAA P10253 1/20 0.42
BRAF P15056 1/20 0.41
NPC1 O15118 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CFTR P13569 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20476685 0.89 IKBKB (0.46) ALDH1A1HPGDSMN1; SMN2MAP4K1HSP90AA1
SCHEMBL21565914 0.86 ALDH1A1 (0.41) ALDH1A1HPGDSMN1; SMN2MAP4K1HSP90AA1
SCHEMBL6865515 0.84 MAPT (0.48) ALDH1A1HPGDSMN1; SMN2HSP90AA1PDK2
SCHEMBL21544269 0.83 ALDH1A1 (0.44) ALDH1A1HPGDSMN1; SMN2HSP90AA1PDK2
SCHEMBL1708822 0.82 KMT2A (0.57) ALDH1A1HPGDSMN1; SMN2MAP4K1ABL1
SCHEMBL29447970 0.81 PDK2 (0.47) ALDH1A1HPGDSMN1; SMN2HSP90AA1PDK2
SCHEMBL384544 0.81 MAPT (0.46) ALDH1A1HPGDSMN1; SMN2HSP90AA1PDK2
SCHEMBL13205433 0.81 PDK2 (0.47) ALDH1A1HPGDSMN1; SMN2HSP90AA1PDK2
SCHEMBL5065113 0.81 PDK2 (0.47) ALDH1A1MAP4K1HSP90AA1PDK2ABL1
SCHEMBL3806699 0.81 MAPT (0.51) ALDH1A1SMN1; SMN2MAP4K1ABL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA ALDH1A1 2279/4885HPGD 2416/4885SMN1; SMN2 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.